Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 3Carcinoma, Renal Cell 3Virus Diseases 1Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1Adenoviridae Infections 1

Interventions

Gemcitabine 2valrubicin 1pembrolizumab 1liposomal doxorubicin 1fludarabine phosphate 1fludarabine 1atezolizumab 1Tumor Necrosis Factor-alpha 1Oncolytic Virotherapy 1Mitomycin 1Interferons 1Interferon-beta 1Immune Checkpoint Inhibitors 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenoviridae Infections × Interferons × Clear all
NCT01438112 2021-04-14

BOND

CG Oncology, Inc.

Phase 2/3 Terminated
22 enrolled
Genitourinary

Adenoviridae Infections, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡